Consensus	consensus	O	O	O	O
statement	statement	O	O	O	O
concerning	concerning	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
occurring	occurring	O	O	O	O
during	during	O	O	O	O
haematopoietic	haematopoietic	O	O	O	O
stem	stem	O	O	O	O
cell	cell	O	O	O	O
transplantation	transplantation	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
autoimmune	autoimmune	O	DISEASE	OTHERS	I
diseases	diseases	O	DISEASE	OTHERS	I
,	,	O	O	O	O
with	with	O	O	O	O
special	special	O	O	O	O
reference	reference	O	O	O	O
to	to	O	O	O	O
systemic	systemic	O	O	OTHERS	I
sclerosis	sclerosis	O	O	OTHERS	I
and	and	O	O	O	O
multiple	multiple	O	DISEASE	OTHERS	I
sclerosis	sclerosis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Autologous	autologous	O	O	O	O
haematopoietic	haematopoietic	O	O	O	O
stem	stem	O	O	O	O
cell	cell	O	O	O	O
transplantation	transplantation	O	O	O	O
is	is	O	O	O	O
now	now	O	O	O	O
a	a	O	O	O	O
feasible	feasible	O	O	O	O
and	and	O	O	O	O
effective	effective	O	O	O	O
treatment	treatment	O	O	O	O
for	for	O	O	O	O
selected	selected	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
severe	severe	O	O	O	O
autoimmune	autoimmune	O	DISEASE	OTHERS	I
diseases	diseases	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Worldwide	worldwide	O	O	O	O
,	,	O	O	O	O
over	over	O	O	O	O
650	650	O	O	O	O
patients	patients	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
transplanted	transplanted	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
context	context	O	O	O	O
of	of	O	O	O	O
phase	phase	O	O	O	O
I	i	O	O	O	O
and	and	O	O	O	O
II	ii	O	O	O	O
clinical	clinical	O	O	O	O
trials	trials	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
results	results	O	O	O	O
are	are	O	O	O	O
encouraging	encouraging	O	O	O	O
enough	enough	O	O	O	O
to	to	O	O	O	O
begin	begin	O	O	O	O
randomised	randomised	O	O	O	O
phase	phase	O	O	O	O
III	iii	O	O	O	O
trials	trials	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
as	as	O	O	O	O
predicted	predicted	O	O	O	O
,	,	O	O	O	O
significant	significant	O	O	O	O
transplant-related	transplant-related	O	O	O	O
morbidity	morbidity	O	O	O	O
and	and	O	O	O	O
mortality	mortality	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
observed	observed	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
is	is	O	O	O	O
primarily	primarily	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
complications	complications	O	O	O	O
related	related	O	O	O	O
to	to	O	O	O	O
either	either	O	O	O	O
the	the	O	O	O	O
stage	stage	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
disease	disease	O	O	O	O
at	at	O	O	O	O
transplant	transplant	O	O	O	O
or	or	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
infections	infections	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
number	number	O	O	O	O
of	of	O	O	O	O
deaths	deaths	O	DISEASE	OTHERS	I
related	related	O	O	O	O
to	to	O	O	O	O
cardiac	cardiac	O	DISEASE	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
is	is	O	O	O	O
low	low	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
caution	caution	O	O	O	O
is	is	O	O	O	O
required	required	O	O	O	O
when	when	O	O	O	O
cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
anthracyclines	anthracyclines	O	O	OTHERS	I
such	such	O	O	O	O
as	as	O	O	O	O
mitoxantrone	mitoxantrone	CHEMICALS	O	OTHERS	I
are	are	O	O	O	O
used	used	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
possible	possible	O	O	O	O
underlying	underlying	O	O	O	O
heart	heart	O	O	OTHERS	I
damage	damage	O	O	OTHERS	I
,	,	O	O	O	O
for	for	O	O	O	O
example	example	O	O	O	O
,	,	O	O	O	O
systemic	systemic	O	O	OTHERS	I
sclerosis	sclerosis	O	O	OTHERS	I
patients	patients	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
November	november	O	O	O	O
2002	2002	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
meeting	meeting	O	O	O	O
was	was	O	O	O	O
held	held	O	O	O	O
in	in	O	O	O	O
Florence	florence	O	O	O	O
,	,	O	O	O	O
bringing	bringing	O	O	O	O
together	together	O	O	O	O
a	a	O	O	O	O
number	number	O	O	O	O
of	of	O	O	O	O
experts	experts	O	O	O	O
in	in	O	O	O	O
various	various	O	O	O	O
fields	fields	O	O	O	O
,	,	O	O	O	O
including	including	O	O	O	O
rheumatology	rheumatology	O	O	O	O
,	,	O	O	O	O
cardiology	cardiology	O	O	O	O
,	,	O	O	O	O
neurology	neurology	O	O	O	O
,	,	O	O	O	O
pharmacology	pharmacology	O	O	O	O
and	and	O	O	O	O
transplantation	transplantation	O	O	O	O
medicine	medicine	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
object	object	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
meeting	meeting	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
analyse	analyse	O	O	O	O
existing	existing	O	O	O	O
data	data	O	O	O	O
,	,	O	O	O	O
both	both	O	O	O	O
published	published	O	O	O	O
or	or	O	O	O	O
available	available	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
European	european	O	O	O	O
Group	group	O	O	O	O
for	for	O	O	O	O
Blood	blood	O	O	O	O
and	and	O	O	O	O
Marrow	marrow	O	O	O	O
Transplantation	transplantation	O	O	O	O
autoimmune	autoimmune	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
database	database	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
to	to	O	O	O	O
propose	propose	O	O	O	O
a	a	O	O	O	O
safe	safe	O	O	O	O
approach	approach	O	O	O	O
to	to	O	O	O	O
such	such	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
full	full	O	O	O	O
cardiological	cardiological	O	O	O	O
assessment	assessment	O	O	O	O
before	before	O	O	O	O
and	and	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
transplant	transplant	O	O	O	O
emerged	emerged	O	O	O	O
as	as	O	O	O	O
the	the	O	O	O	O
major	major	O	O	O	O
recommendation	recommendation	O	O	O	O
.	.	O	O	O	O

